GSK ' s ViiV Says Study Shows Its Long-Acting HIV Shot as Effective as Gilead ' s Daily Pill GSK ' s ViiV Says Study Shows Its Long-Acting HIV Shot as Effective as Gilead ' s Daily Pill

British drugmaker GSK ' s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news